| Name | Title | Contact Details |
|---|---|---|
Myron Holubiak |
Chief Executive Officer | Profile |
Elabscience is a biotech corporation that specializes in laboratory reagents for life science research, including ELISA kits, FCM antibodies, biochemical kits, antibodies, and proteins.
Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite`s strategy includes assisting partner companies in the life cycle management of products, to improve off-patent drug products, and developing generic versions of controlled release drug products with high barriers to entry. Elite has four ANDA products partnered with TAGI Pharma; one ANDA has launched, two ANDAs are in the process of a manufacturing site transfer and an additional ANDA is currently under review by the FDA. Elite also manufactures Lodrane D® and receives royalties for Lodrane D®, an allergy product partnered with ECR Pharmaceuticals (“ECR”), a wholly owned subsidiary of Hi-Tech Pharmacal (“Hi-Tech”). Elite`s lead pipeline products, ELI-216, a once-daily abuse resistant oxycodone, and ELI-154, a once-daily oxycodone, are novel sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also has partnered with Mikah Pharma to develop a new product and with Hi-Tech Pharmacal to develop an intermediate for a generic product.
Founded in 2017, Action Behavior Centers (ABC) is a leading Applied Behavior Therapy (ABA) provider offering comprehensive services and support to improve the lives of children on the autism spectrum. The provider`s high-quality, center-based care combined with its dedication to helping young children reach their full potential has made ABC one of the fastest growing and highest quality providers in the industry. Headquartered in Austin, Texas, ABC operates 54 clinics in Texas, Arizona and Colorado.
We are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. We are committed to improving patients` lives and addressing the liver community`s most pressing needs. Our corporate headquarters is located in New York, and we have additional offices in San Diego, London and Perugia.
Beckman Coulter Inc. is a Danaher Corporation company that develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing.